OMGA News and Press, Omega Therapeutics Inc. From 05/04/22

Omega Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire Investigational New Drug Application for OTX-2002 for MYC Driven Hepatocellular Carcinoma on Track to be Submitted in the First Half of 2022 ...

Omega Therapeutics to Unveil Preclinical Data on Epigenomic Programming of MYC with Epigenomic Controllers as a Promising Therapeutic Approach in Non-Small Cell Lung Cancer at the 25th Annual ASGCT Meeting PR Newswire Regulation of MYC gene expression via epigenomic pr...

Omega Therapeutics (NASDAQ:OMGA) has appointed Joshua Reed as CFO, effective May 23, 2022. Current CFO Roger Sawhney will transition to the role of Chief Business Officer. Most recently, Reed served as CFO at Aldeyra Therapeutics. For further details see: Omega Therapeutics appoints Jos...

Omega Therapeutics Announces Appointment of Joshua Reed as Chief Financial Officer PR Newswire Roger Sawhney , M.D. to serve as Chief Business Officer CAMBRIDGE, Mass. , April 29, 2022 /PRNewswire/ -- Omega Therapeutics (NASDAQ: OMGA) (Omega), a developme...

Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022 PR Newswire OTX-2002 suppresses c-Myc gene expression resulting in a loss of cancer cell ...

Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth PR Newswire Kevin McManus Appointed as Chief Human Resources Officer Ling Zeng, Esq. , Appointed as Chief Legal and Administrative Officer CAMBRIDGE, Mass. ...

Omega Therapeutics press release (NASDAQ:OMGA): Q4 GAAP EPS of -$0.44 beats by $0.19. Revenue of $0.14M. For further details see: Omega Therapeutics GAAP EPS of -$0.44 beats by $0.19, revenue of $0.14M

Omega Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Outlines Key Corporate Objectives for 2022 - Investigational New Drug Application for OTX-2002 for c-Myc Driven Hepatocellular Carcinoma On Track to be Submitted in the First Half of 2022 - Ad...

Omega Therapeutics to Present Preclinical Data for OTX-2002 at the American Association for Cancer Research Annual Meeting 2022 PR Newswire CAMBRIDGE, Mass. , March 8, 2022 /PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a development-stag...

Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs PR Newswire CAMBRIDGE, Mass. , Feb. 28, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology a...